Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn's disease perianal fistulas.
The long-term safety and efficacy of allogeneic bone marrow-derived mesenchymal stromal cell (bmMSC) therapy in perianal Crohn's disease (CD) fistulas is unknown. We aimed to provide a 4-year clinical evaluation of allogeneic bmMSC treatment of perianal CD fistulas. A double-blind dose-finding study for local bmMSC-therapy in 21 patients with refractory perianal fistulising Crohn's disease was performed at the Leiden University Medical Center in 2012-2014. All patients treated with bmMSCs (1x107 bmMSCs cohort 1, n=5; 3x107 bmMSCs cohort 2, n=5; 9x107 bmMSCs cohort 3, n=5) were invited for a 4-year evaluation. Clinical events were registered, fistula closure was evaluated and anti-human leukocyte antigen (HLA) antibodies were assessed. Patients were also asked to undergo a pelvic MRI scan and rectoscopy. Thirteen out of 15 patients (87%) treated with bmMSCs were available for long-term follow-up. Two non-MSC related malignancies were observed. No serious adverse events thought to be related to bmMSC-therapy were found. In cohort 2 (n=4) all fistulas were closed 4 years after bmMSC-therapy. In cohort 1 (n=4) 63% and cohort 3 (n=5) 43% of the fistulas were closed. In none of the patients anti-HLA antibodies could be detected 24 weeks and 4 years after therapy. Pelvic MRI scans showed significantly smaller fistula tracts after 4 years. Allogeneic bmMSC-therapy for CD associated perianal fistulas is also on the long-term a safe therapy. In bmMSC treated patients, fistulas with closure at week 24 were still closed after 4 years. (ClinicalTrials.gov ID NCT01144962).